Prosight Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Prosight Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-22,900	Closed	-$1.94M	–	55
2020 Q1	$1.94M	Sell	22,900 -69,837	-75%	-$6.02M	0.9%	28
2019 Q4	$7.84M	Buy	92,737 +2,785	+3%	+$210K	3.44%	13
2019 Q3	$6.06M	Buy	89,952 +38,752	+76%	+$2.98M	3.36%	12
2019 Q2	$4.38M	Sell	51,200 -6,184	-11%	-$529K	2.21%	16
2019 Q1	$5.1M	Sell	57,384 -45,616	-44%	-$4.23M	2.23%	16
2018 Q4	$8.77M	Buy	103,000 +6,572	+7%	+$625K	4.53%	8
2018 Q3	$9.35M	Buy	96,428 +38,528	+67%	+$3.85M	5.21%	5
2018 Q2	$5.45M	Sell	57,900 -5,500	-9%	-$482K	4%	10
2018 Q1	$5.14M	Buy	+63,400	New	+$5.44M	3.22%	12

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Prosight Management's BMRN Position: Q2 2020 in Review

Prosight Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 22,900 shares — an estimated $1.94M sold.

Prosight Management first reported a position in BMRN in Q1 2018 and held it in 9 quarters. The position peaked at $9.35M in Q3 2018. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

Prosight Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Prosight Management sold 22,900 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $1.94M.
Prosight Management first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Prosight Management's BioMarin Pharmaceuticals position peaked at $9.35M in Q3 2018.
527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.